MarketScreener Homepage > Equities > Nasdaq > DexCom, Inc. DXCM

Report

Delayed Nasdaq - 01/20 04:00:00 pm
364.12	USD		+1.81%

01/19

DEXCOM SCHEDULES FOURTH QUARTER AND FULL YEAR 2020 EARNINGS RELEASE AND CONFERENCE CALL FOR FEBRUARY 11, 2021 AT 4 : 30 p.m. Eastern Time

01/15

DEXCOM : Insider Selling in Dexcom (DXCM) Shares Continues

01/14

INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Dexcom

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/13/2021	01/14/2021	01/15/2021	01/19/2021	01/20/2021	Date
362.55(c)	352.08(c)	354.2(c)	357.64(c)	364.12	Last
986 825	890 619	752 952	794 548	1 162 819	Volume
+0.66%	-2.89%	+0.60%	+0.97%	+1.81%	Change

More quotes

Financials (USD)

Sales 2020	1 913 M - -
Net income 2020	218 M - -
Net Debt 2020	24,3 M - -
P/E ratio 2020	159x
Yield 2020	-

Sales 2021	2 331 M - -
Net income 2021	302 M - -
Net cash position 2021	328 M - -
P/E ratio 2021	118x
Yield 2021	-

Capitalization	34 343 M 34 343 M -
EV / Sales 2020	18,0x
EV / Sales 2021	14,6x
Nbr of Employees	3 900
Free-Float	98,8%

More Financials

Company

DexCom, Inc. specialises in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 78.7% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

02/11

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of DexCom, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about DEXCOM, INC.

01/19	DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time	BU
01/15	DEXCOM : Insider Selling in Dexcom (DXCM) Shares Continues	MT
01/14	INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Dexcom	MT
01/11	DEXCOM : Guides Q4, 2020 Revenue Above Analysts' Estimates; 2021 Revenue In Line..	MT
01/11	DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..	AQ
01/11	DEXCOM : Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fisca..	BU
01/07	INSIDER TRENDS : Insider 90-Day Selling Trend Extended at Dexcom	MT
01/06	DEXCOM : UBS Raises DexCom to Buy From Neutral, PT to $445 From $410, Citing Pha..	MT
01/05	DEXCOM : to Present at 39th Annual J.P. Morgan Healthcare Conference	BU
2020	INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Dexcom	MT
2020	INSIDER TRENDS : Dexcom Insider Continues 90-Day Selling Trend	MT
2020	Equities End Mixed as Concerns Over New Coronavirus Strain Take Focus From Pa..	MT
2020	INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Dexcom	MT
2020	DEXCOM : Morgan Stanley Adjusts DexCom PT to $402 From $398, Maintains Equal Wei..	MT
2020	DEXCOM INC : Change in Directors or Principal Officers (form 8-K)	AQ

More news

News in other languages on DEXCOM, INC.

2020	DEXCOM : Le système Dexcom G6 de mesure en continu du glucose bientôt remboursé ..
2020	DEXCOM, INC. : publication des résultats trimestriels
2020	DEXCOM, INC. : Veröffentlichung des Quartalsergebnisses
2020	DEXCOM, INC. : publication des résultats semestriels
2020	DEXCOM, INC. : Veröffentlichung des Halbjahresergebnisses

More news

Analyst Recommendations on DEXCOM, INC.

01/06	DEXCOM : UBS Raises DexCom to Buy From Neutral, PT to $445 From $410, Citing Pha..	MT
2020	DEXCOM : Morgan Stanley Adjusts DexCom PT to $402 From $398, Maintains Equal Wei..	MT
2020	Canaccord Genuity Adjusts DexCom's Price Target to $435 From $475, Maintains ..	MT

More recommendations

Provided by Scoopnest.com

Chart DEXCOM, INC.

Duration : Period :

DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener

Full-screen chart

Technical analysis trends DEXCOM, INC.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	21
Average target price	447,17 $
Last Close Price	357,64 $
Spread / Highest target	51,0%
Spread / Average Target	25,0%
Spread / Lowest Target	-32,9%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Kevin Ronald Sayer	Chairman, President & Chief Executive Officer
Quentin S. Blackford	Chief Operating & Financial Officer
Andrew K. Balo	EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach	Chief Technology Officer & Executive VP
Shelly R. Selvaraj	Senior Vice President-Information Technology

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

DEXCOM, INC.	-3.27%	34 343



ABBOTT LABORATORIES	2.81%	192 878
MEDTRONIC PLC	1.00%	159 248
BECTON, DICKINSON AND COMPANY	4.22%	75 845
HOYA CORPORATION	-5.12%	49 012
ALIGN TECHNOLOGY, INC.	4.31%	43 952

More Results